Health care delivery
Algorithm based medicine
Investment philosohophy
Cognitive and behavioral science
About Tomas Forslund
Tomas Forslund is a specialist in family medicine with 20 years of broad clinical experience encompassing cardiology, internal medicine, oncology, general practice and home care.
He holds an MD and a PhD in Pharmacoepidemiology from Karolinska Insitutet and is since 2014 a Medical Advisor to the Stockholm Region. He serves in several National and Regional Committees developing clinical guidelines and treatment recommendations.
Tomas is a self taught programmer and is the author of ~20 peer reviewed academic papers performing observational research in large datasets. He has extensive experience visualizing important insights using descriptive statistics, regression models and prediction models.
When he is not working or spending time with his two boys you can find him in the outdoors hiking, bikepacking, mountainbiking, climbing, cayaking, swimming or running.
- balance leverage, stock and bond funds, and other investments to reach the efficient frontier?
- rationally use back tests to invest for the future?
- keep your behavioral biases in check?
- keep investing rationally without caring about short term performance?
- avoid identifying with your investment performance?
- know if you have "enough"?
- go from manual managament of chronic conditions to automatically triggering the algorithms from recent guidelines?
- efficiently communicate prescribed measurements, blood test and referrals with the patients?
- automate patient specific educational disease and treatment information?
- provide patient specific and relevant risk scoring and decisions supports?
- automate generation of treatment plans/patient contracts?
- understand your limits so you can keep pushing them?
- adopt and enjoy long term beneficial behaviors?
- help others improve?
- learn when to give up and when to push harder?
- merge your rational self with your subconsciuos dreams and desires?
- understand who you really are and what you really want?
- find meaning and purpose when you have "enough"?
- improve adoption to new guidelines?
- balance compliance to guidelines with a patient centric view?
- adapt guidelines to deal with multimorbidity and polypharmacy?
- combine digital and physical care in an efficient and safe way?
'%20fill%3D'%23c58f56'%20fill-rule%3D'nonzero'%3E%3Cpath%20d%3D'M6.63378906,12.0097656%20L6.63378906,6.61621094%20L3.43457031,6.61621094%20C3.37988281,6.08300781%203.48242188,5.515625%203.7421875,4.9140625%20C4.20703125,3.79296875%205.14355469,3.02734375%206.55175781,2.6171875%20L6.55175781,2.6171875%20L6.55175781,0.484375%20C4.70605469,0.853515625%203.28759766,1.62255859%202.29638672,2.79150391%20C1.30517578,3.96044922%200.809570312,5.59082031%200.809570312,7.68261719%20L0.809570312,7.68261719%20L0.809570312,12.0097656%20L6.63378906,12.0097656%20Z'%2F%3E%3Cpath%20d%3D'M13.6337891,12.0097656%20L13.6337891,6.61621094%20L10.4345703,6.61621094%20C10.3798828,6.08300781%2010.4824219,5.515625%2010.7421875,4.9140625%20C11.2070312,3.79296875%2012.1435547,3.02734375%2013.5517578,2.6171875%20L13.5517578,2.6171875%20L13.5517578,0.484375%20C11.7060547,0.853515625%2010.2875977,1.62255859%209.29638672,2.79150391%20C8.30517578,3.96044922%207.80957031,5.59082031%207.80957031,7.68261719%20L7.80957031,7.68261719%20L7.80957031,12.0097656%20L13.6337891,12.0097656%20Z'%2F%3E%3Cpath%20d%3D'M16.8095703,24.3994141%20C18.6279297,24.0439453%2020.0395508,23.2714844%2021.0444336,22.0820312%20C22.0493164,20.8925781%2022.5517578,19.265625%2022.5517578,17.2011719%20L22.5517578,17.2011719%20L22.5517578,12.8740234%20L16.7070312,12.8740234%20L16.7070312,18.2675781%20L19.9267578,18.2675781%20C19.9677734,18.8828125%2019.8515625,19.4912109%2019.578125,20.0927734%20C19.0722656,21.1044922%2018.1494141,21.8222656%2016.8095703,22.2460938%20L16.8095703,22.2460938%20L16.8095703,24.3994141%20Z'%2F%3E%3Cpath%20d%3D'M23.8095703,24.3994141%20C25.6279297,24.0439453%2027.0395508,23.2714844%2028.0444336,22.0820312%20C29.0493164,20.8925781%2029.5517578,19.265625%2029.5517578,17.2011719%20L29.5517578,17.2011719%20L29.5517578,12.8740234%20L23.7070312,12.8740234%20L23.7070312,18.2675781%20L26.9267578,18.2675781%20C26.9677734,18.8828125%2026.8515625,19.4912109%2026.578125,20.0927734%20C26.0722656,21.1044922%2025.1494141,21.8222656%2023.8095703,22.2460938%20L23.8095703,22.2460938%20L23.8095703,24.3994141%20Z'%2F%3E%3C%2Fg%3E%3C%2Fg%3E%3C%2Fsvg%3E)
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hallas J, Olesen M, Bennie M, Mueller T, Carragher R, Karlstad Ø, Kjerpeseth LJ, Klungel OH. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. Eur Heart J. 2022;43:3528-3538.
Forslund T, Braunschweig F, Holzmann MJ, Siddiqui AJ. Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation. J Am Heart Assoc. 2021. doi: 10.1161/JAHA.121.021716.
Komen J, Pottegård A, Hjemdahl P, Mantel-Teeuwisse AK, Wettermark B, Hellfritzsch M, Hallas J, Herings R, Smits L, Forslund T, Klungel O. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart. 2021. doi: 10.1136/heartjnl-2021-319332.
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hellfritzsch M, Hallas J, Olesen M, Bennie M, Mueller T, Voss A, Schink T, Haug U, Kollhorst B, Karlstad Ø, Kjerpeseth LJ, Klungel OH. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021. doi: 10.1093/europace/euab091.
Komen JJ, Belitser SV, Wyss R, Schneeweiss S, Taams AC, Pajouheshnia R, Forslund T, Klungel OH. Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study. Pharmacoepidemiol Drug Saf. 2021;30:934-951. doi: 10.1002/pds.5232.
Forslund T, Carlsson AC, Ljunggren G, Ärnlöv J, Wachtler C. Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Fam Pract. 2020:cmaa056. doi: 10.1093/fampra/cmaa056.
Forslund T, Kosidou K, Wicks S, Dalman C. Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study. BMC Psychiatry. 2020;20:328.
Komen JJ, Heerdink ER, Klungel OH, Mantel-Teeuwisse AK, Forslund T, Wettermark B, Hjemdahl P. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother. 2020; doi: 10.1093/ehjcvp/pvaa017
Komen JJ, Forslund T, Mantel-Teeuwisse AK, Klungel OH, von Euler M, Braunschweig F, Wallén H, Hjemdahl P. Association of Preceding Antithrombotic Therapy in Atrial Fibrillation Patients with Ischemic Stroke, Intracranial Hemorrhage, or Gastrointestinal Bleed and Mortality. Eur Heart J Cardiovasc Pharmacother. 2019; doi: 10.1093/ehjcvp/pvz063
Wändell P, Forslund T, Danin Mankowitz H, Ugarph-Morawski A, Eliasson S, Braunschwieg F, Holmström M. Venous thromboembolism 2011–2018 in Stockholm: a demographic Study. J Thromb Thrombolysis. 2019;48:668-673.
Forslund T. Wettermark B. Primärvårdens roll i sjukvårdssystemet. Hälso- och sjukvårdsförvaltningen, Region Stockholm, 2019.
Komen J, Hjemdahl P, Mantel-Teeuwisse AK, Klungel OH, Wettermark B, Forslund T. Concomitant anticoagulant and antidepressant therapy in atrial fibrillation patients and risk of stroke and bleeding. Clinical Pharmacology & Therapeutics. 2019; doi: 10.1002/cpt.1603
Hjemdahl P, Braunschweig F, Holmström M, Johnsson H, von Euler M, Wallén H, Forslund T. Förbättrad strokeprevention vid förmaksflimmer med NOAK. Erfarenheter från Stockholms Län. Lakartidningen. 2018;115. pii: FAH6
Forslund T, Roos F, Wettermark B. Tillgänglighet i primärvården. Till vem, för vad och på vilket sätt? Hälso- och sjukvårdsförvaltningen, Stockholms Läns Landsting, 2018.
Forslund T, Komen J, Andersen M, Wettermark B, von Euler M, Mantel-Teeuwisse AK, Braunschweig F, Hjemdahl P. Improved stroke prevention in atrial fibrillation after the introduction of NOACs - the Stockholm experience. Stroke. 2018;49:2122-8.
Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with NOAC or warfarin treatment in patients with non-valvular atrial fibrillation: a population based cohort study. Europace. 2018;20:420-428.
Loikas D, Forslund T, Wettermark B, Schenk-Gustafsson K, Hjemdahl P, von Euler M. Sex and Gender Differences in Thromboprophylactic Treatment of Patients with Atrial Fibrillation After the Introduction of Non.Vitamin K Oral Anticoagulants. Am J Cardiol. 2017;120:1302-1308
Komen J, Forslund T, Hjemdahl P, Wettermark B. Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. Eur J Clin Pharmacol. 2017;73:1315-1322.
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. 2017;83:642-652.
Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72:329-38.
Forslund T, von Euler M, Johnsson H, Holmström M, Wettermark B, Hjemdahl P. Fler med förmaksflimmer får antikoagulantia sedan NOAK kom. Lakartidningen. 2015;112:CZYS
Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70:1477-85.
Forslund T, Wettermark B, Wandell P, von Euler M Hasselstrom J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. lnt J Cardiol. 2013;170:208-14
Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Usage, Risk and Benefit of Weight-Loss Drugs in Primary Care. J Obes. 2011;2011:459263
Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B.Bantningsläkemedel tycks inte göra någon nytta. Läkartidningen. 2010;107:910-913
Forslund T, 100 % hälsa på jobbet, Redaktionen, 2006
Forslund T, Technology Transfer in Europe – Comparing Five Regions, Karolinska Institutet, 2002
